EarningsQ2 2026 Earnings Report
CSBTF Q2 2026 EPS Results
Actual EPS$0.07
Consensus EPS$0.07
Beat/MissBeat by +<$0.01
One Year Ago EPS-$0.04
CSBTF Q2 2026 Revenue Results
Actual Revenue$90.68M
Expected Revenue$47.60M
Beat/MissBeat by +$43.08M
YoY Revenue Growth+32.78%
Earnings Announcement Details
QuarterQ2 2026
Date08/13/2026
TimeBefore Open
Conference CallThursday, August 13, 2026
CSBTF Upcoming Earnings
Kuros Biosciences's next earnings date is estimated for March 17, 2027, based on past reporting schedules.
Q2 2026 Earnings Call Audio
CSBTF Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call communicated a strong set of operational and financial achievements (robust +45% H1 revenue growth, first sustained half‑year profitability with CHF 12.5M adjusted EBITDA and CHF 4.4M net profit, improving gross margins, strong clinical evidence and a clear midterm revenue/margin target). These positives are tempered by planned near‑term investments and transformation costs, expected dilution from the U.S. manufacturing ramp, lumpiness in international revenue, and working capital accumulation that creates short-term liquidity sensitivity. On balance, the transformational investments are framed as deliberate and the company maintained conservative near-term guidance while presenting a credible path to >20% adjusted EBITDA by 2028, so the overall tone is confident with manageable near-term risks.Company Guidance
Strong H1 2026 Revenue Growth
Total medical device sales of $92.4M in H1 2026, representing +45% year-over-year growth vs H1 2025; direct MagnetOs sales grew +46%, and revenue has increased ~566% since H1 2023 (demonstrating rapid scale).
First Half-Year Profitability Inflection
Adjusted EBITDA of CHF 12.5M (13.6% adjusted EBITDA margin) and net profit of CHF 4.4M for the period (vs a CHF 2M loss prior year). EPS improved from a loss of CHF 0.05 to earnings of CHF 0.11.
Operating Leverage and Margin Expansion
Since H1 2023 fixed costs increased ~271% while revenue grew ~566%, indicating operating leverage; gross profit margin improved (management cited a ~2.1 percentage point uplift) driven by volume growth, unit cost optimization and supply chain productivity.
Clinical Evidence and Published Results
Published retrospective study in high-risk ACDF patients reported a 97.7% six-month fusion rate (CT-assessed) in a population with 63% having three or more comorbidities; three Level 1 trials underway (PROOF 83% enrolled, PRECISE 49% enrolled, ASTRA 14% enrolled).
Commercial Expansion and Market Share Gains
Distributor reach grew +34% vs H1 2025; hospital account growth and surgeon utilization increasing (surgeon penetration cited at ~16%); management estimates market share has increased approximately fourfold since 2023. More than 150,000 patients treated worldwide with MagnetOs since launch.
Clear Midterm Financial Guidance
Company expects revenue to more than double from CHF 146M in 2025 to CHF 300–330M by 2028 and targets an adjusted EBITDA margin above 20% by 2028; for 2026 management expects growth of approximately 35%.
Balance Sheet and Liquidity Position
Debt-free balance sheet; closed June with CHF 9.7M cash and CHF 44.4M receivables (CHF 54.2M combined). Undrawn CHF 12.4M bridge facility available as a backstop; management expects organic plan to be funded via operating cash flow.
Operational Investments and Dual-Source Manufacturing
U.S. Alpharetta manufacturing facility expected to go live in H2 2026, creating dual-source production with Bilthoven (Netherlands) to improve supply resilience and support localized fulfillment and future margin expansion; targeted CapEx for the build ~CHF 11–12M (U.S.), CHF 2–3M (Netherlands) and ~CHF 1M IT.
CSBTF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed